Computationally Guided Design of BCR-ABL Tyrosine Kinase Inhibitors
C. Duan, S. K. S. Chu, J. B. Siegel, J. S. Fell
The paper designs two new BCR-ABL tyrosine kinase inhibitors with predicted improved binding affinity over imatinib for advanced chronic myeloid leukemia treatment.
bioRxiv · Aug 20, 2020 · PreprintPharmacology & Toxicology